<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Contribution of oxaliplatin to treatment of localized rectal cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Contribution of oxaliplatin to treatment of localized rectal cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">Contribution of oxaliplatin to treatment of localized rectal cancer</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Study<br/> author, year</td> <td class="subtitle1">RT dose, Gy</td> <td class="subtitle1">Chemotherapy during RT</td> <td class="subtitle1">Adjuvant chemotherapy</td> <td class="subtitle1">Long-term outcomes</td> </tr> <tr class="divider_bottom"> <td> <p>STAR-01</p> Aschele C, 2016<sup>[1]</sup></td> <td class="centered">50.4</td> <td class="centered"> <p>FU</p> <p>(225 mg/m<sup>2</sup>/day)</p> <p>+/–</p> <p>oxaliplatin</p> (60 mg/m<sup>2</sup> weekly)</td> <td class="centered">FU-based adjuvant therapy was encouraged but not specified</td> <td class="centered">No SS difference in OS</td> </tr> <tr> <td class="divider_bottom" rowspan="2"> <p>ACCORD/PRODIGE1</p> Gerard JP, 2010, 2012<sup>[2,3]</sup></td> <td class="centered">45</td> <td class="centered"> <p>Capecitabine</p> <p>(800 mg twice daily, 5 days/week)</p> <strong>versus</strong></td> <td class="centered divider_bottom" rowspan="2"> <p>Left to discretion of participating institutes</p> <p>+</p> not reported</td> <td class="divider_bottom centered" rowspan="2">No SS difference in OS</td> </tr> <tr class="divider_bottom"> <td class="centered">50</td> <td class="centered"> <p>Capecitabine</p> <p>(800 mg twice daily, 5 days/week)</p> <p>+</p> <p>oxaliplatin</p> (50 mg/m<sup>2</sup> weekly)</td> </tr> <tr> <td class="divider_bottom" rowspan="2"> <p>PETACC-6</p> Schmoll HJ, 2018<sup>[4]</sup></td> <td class="centered divider_bottom" rowspan="2">45 (optional boost to 50.4)</td> <td class="centered"> <p>Capecitabine</p> <p>(825 mg/m<sup>2</sup> twice daily)</p> <strong>versus</strong></td> <td class="centered"> <p>Capecitabine</p> <p>(1000 mg/m<sup>2</sup> twice daily, days 1 to 15, every 21 days for 6 months)</p> <strong>versus</strong></td> <td class="divider_bottom centered" rowspan="2">No SS difference in DFS, OS, or locoregional control</td> </tr> <tr class="divider_bottom"> <td class="centered"> <p>Capecitabine</p> <p>+</p> <p>oxaliplatin</p> (50 mg/m<sup>2</sup> weekly)</td> <td class="centered"> <p>Same capecitabine dose</p> <p>+</p> <p>oxaliplatin</p> (130 mg/m<sup>2</sup> every 3 weeks for 6 months)</td> </tr> <tr> <td class="divider_bottom" rowspan="2"> <p>CAO/ARO</p> Rodel C, 2012, 2015<sup>[5,6]</sup></td> <td class="centered divider_bottom" rowspan="2">50.4</td> <td class="centered"> <p>FU infusion</p> <p>(1000 mg/m<sup>2</sup>/day, days 1 to 5 and 29 to 33)</p> <strong>versus</strong></td> <td class="centered"> <p>Bolus FU</p> <p>(500 mg/m<sup>2</sup> days 1 to 5 monthly for 4 months)</p> <strong>versus</strong></td> <td class="divider_bottom centered" rowspan="2">Three-year DFS 75.9 versus 71.2%, HR 0.79 (95% CI 0.64-0.98)</td> </tr> <tr class="divider_bottom"> <td class="centered"> <p>FU infusion</p> <p>(250 mg/m<sup>2</sup>/day, days 1 to 14 and 22 to 35)</p> <p>+</p> <p>oxaliplatin</p> (50 mg/m<sup>2</sup> weekly)</td> <td class="centered"> <p>FOLFOX</p> (day 1 and 15 every 28 days for 4 months)</td> </tr> <tr> <td rowspan="2"> <p>NSABP R-04</p> Allegra CJ, 2015<sup>[7]</sup></td> <td class="centered" rowspan="2">50.4</td> <td class="centered"> <p>FU infusion</p> <p>(225 mg/m<sup>2</sup>/day)</p> <p>+/–</p> <p>oxaliplatin</p> <p>(50 mg/m<sup>2</sup> weekly)</p> <strong>or</strong></td> <td class="centered" rowspan="2">FU-based adjuvant therapy was encouraged but not specified</td> <td class="centered" rowspan="2">No difference in OS, DFS, or locoregional control</td> </tr> <tr> <td class="centered"> <p>Capecitabine</p> <p>(825 mg/m<sup>2</sup> twice daily)</p> <p>+/–</p> <p>oxaliplatin</p> (50 mg/m<sup>2</sup> weekly)</td> </tr> </tbody></table></div><div class="graphic_footnotes">RT: radiation therapy; FU: fluorouracil; SS: statistically significant; OS: overall survival; DFS: disease-free survival; FOLFOX: short-term infusional FU plus leucovorin and oxaliplatin HR: hazard ratio.</div><div class="graphic_reference">Prepared with data from: 

<ol>
<li>Aschele C, Lonardi S, Cionini L, et al. Final results of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer. J Clin Oncol 2016; 34:3521.</li>
<li>Gérard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28:1638.</li>
<li>Gérard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012; 30:4558.</li>
<li>Schmoll H-J, Stein A, Van Cutsem E, et al. Pre- and postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer: PETACC 6 trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. J Clin Oncol 2020; :JCO2001740.</li>
<li>Rödel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13:679.</li>
<li>Rödel C, Graeven U, Fietkau R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2015; 16:979.</li>
<li>Allegra CJ, Yothers G, O'Connell MJ, et al. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst 2015.</li></ol></div><div id="graphicVersion">Graphic 97598 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
